Blocklisting - 6 Month Review

Hikma Pharmaceuticals Plc 05 October 2007 Block Listing - Six Monthly Review Name of Company: Hikma Pharmaceuticals PLC Name of scheme: Hikma Pharmaceuticals PLC 2004 Stock Option Plan Period of return: From: 6 April 2007 To: 5 October 2007 Balance under block scheme: 1,719,400 ordinary shares of 10 pence each The amount by which the block scheme has Nil been increased, if the scheme has been increased since the date of the last return: Number of securities issued/allotted 314,000 ordinary shares of 10 pence under scheme during period: each Balance under scheme not yet issued/ 1,405,400 ordinary shares of 10 pence allotted at end of period each Number and class of securities originally 166,537,951 ordinary shares of 10 listed and the date of admission pence each originally listed on 1 November 2005 Total number of securities in issue at 169,451,407 ordinary shares of 10 the end of the period pence each - ENDS - Enquiries: Hikma Pharmaceuticals PLC +44 20 7399 2760 Henry Knowles, Company Secretary Susan Ringdal, Investor Relations Director Notes to Editors About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operates through three businesses: 'Branded', 'Injectables' and 'Generics', based principally in the Middle East and North Africa ('MENA'), where it is a market leader and sells across 18 countries, the United States and Europe. In 2006, Hikma achieved revenues of $317 million (2005 $262 million) and profit attributable to shareholders was $55 million (2005 $44 million). At 31 December 2006, the Group had over 2,400 employees. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings